{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:47:43Z","timestamp":1780638463527,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670150"],"award-info":[{"award-number":["81670150"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00262-021-02850-6","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T11:14:29Z","timestamp":1610968469000},"page":"2379-2384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["CAR19\/22 T cell therapy in adult refractory Burkitt\u2019s lymphoma"],"prefix":"10.1007","volume":"70","author":[{"given":"Xiaoxi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1332-9230","authenticated-orcid":false,"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,18]]},"reference":[{"key":"2850_CR1","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.1073\/pnas.79.24.7824","volume":"79","author":"R Dalla-Favera","year":"1982","unstructured":"Dalla-Favera R, Bregni M, Erikson J et al (1982) Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 79:7824\u20137827","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2850_CR2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1200\/JOP.18.00148","volume":"14","author":"K Dunleavy","year":"2018","unstructured":"Dunleavy K (2018) Approach to the diagnosis and treatment of adult Burkitt\u2019s lymphoma. J Oncol Pract 14(11):665\u2013671","journal-title":"J Oncol Pract"},{"key":"2850_CR3","doi-asserted-by":"publisher","first-page":"E114","DOI":"10.1002\/ajh.24720","volume":"92","author":"NJ Short","year":"2017","unstructured":"Short NJ, Kantarjian HM, Ko H et al (2017) Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia\/lymphoma. Am J Hematol 92:E114\u2013E117","journal-title":"Am J Hematol"},{"key":"2850_CR4","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.1996.14.9.2465","volume":"14","author":"JW Sweetenham","year":"1996","unstructured":"Sweetenham JW, Pearce R, Taghipour G et al (1996) Adult Burkitt\u2019s and Burkitt-like non-Hodgkin\u2019s lymphoma\u2014outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 14:2465\u20132472","journal-title":"J Clin Oncol"},{"key":"2850_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bbmt.2012.11.016","volume":"19","author":"LV Maramattom","year":"2013","unstructured":"Maramattom LV, Hari PN, Burns LJ et al (2013) Autologous and allogeneic transplantation for Burkitt lymphoma outcomes and changes in utilization: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 19:173\u2013179","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2850_CR6","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA et al (2017) Axicab-tagene Ciloleucel CART- Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377(26):2531\u20132544","journal-title":"N Engl J Med"},{"issue":"1","key":"2850_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP et al (2019) Tisa-genlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 380(1):45\u201356","journal-title":"N Engl J Med"},{"issue":"1","key":"2850_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood.2019000017","volume":"135","author":"N Wang","year":"2020","unstructured":"Wang N, Hu X, Cao W, Li C, Xiao Y, Cao Y et al (2020) Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies. Blood 135(1):17\u201327","journal-title":"Blood"},{"issue":"12","key":"2850_CR9","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41409-018-0235-0","volume":"53","author":"A Avigdor","year":"2018","unstructured":"Avigdor A, Shouval R, Jacoby E, Davidson T et al (2018) CAR T cells induce a complete response in refractory Burkitt lymphoma. Bone Marrow Transplant 53(12):1583\u20131585","journal-title":"Bone Marrow Transplant"},{"key":"2850_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03198-7","author":"J Du","year":"2020","unstructured":"Du J, Zhang Y (2020) Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review. J Cancer Res Clin Oncol. https:\/\/doi.org\/10.1007\/s00432-020-03198-7","journal-title":"J Cancer Res Clin Oncol"},{"key":"2850_CR11","unstructured":"National Comprehensive Cancer Network (NCCN) (2019) Clinical practice guidelines in oncology. B-cell lymphomas. Version 2.2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed 29 Apr 2019"},{"issue":"2","key":"2850_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188\u2013195","journal-title":"Blood"},{"issue":"1","key":"2850_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-019-0529-9","volume":"7","author":"T Li","year":"2019","unstructured":"Li T, Zhang Y, Peng D, Mao X, Zhou X, Zhou J (2019) A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy. J ImmunoTherapy Cancer 7(1):51","journal-title":"J ImmunoTherapy Cancer"},{"issue":"5","key":"2850_CR14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1634\/theoncologist.2015-0421","volume":"21","author":"MV Maus","year":"2016","unstructured":"Maus MV, Levine BL (2016) Chimeric antigen receptor T-cell therapy for the community oncologist. Oncologist 21(5):608\u2013617","journal-title":"Oncologist"},{"issue":"5","key":"2850_CR15","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.4049\/jimmunol.174.5.3015","volume":"174","author":"CA Ogden","year":"2005","unstructured":"Ogden CA, Pound JD, Batth BK et al (2005) Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt\u2019s lymphoma. J Immunol 174(5):3015\u20133023","journal-title":"J Immunol"},{"issue":"17","key":"2850_CR16","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski M, Kopecky C, Hombach AA, Abken H (2011) IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 71(17):5697\u20135706","journal-title":"Cancer Res"},{"key":"2850_CR17","first-page":"9720912","volume":"2016","author":"Q Guo","year":"2016","unstructured":"Guo Q, Jin Z, Yuan Y et al (2016) New mechanisms of tumor-associated macrophages on promoting tumor progression: recent research advances and potential targets for tumor immunotherapy. J Immunol Res 2016:9720912","journal-title":"J Immunol Res"},{"issue":"1","key":"2850_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","volume":"25","author":"GA Rabinovich","year":"2007","unstructured":"Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25(1):267\u2013296","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"2850_CR19","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L et al (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Investig 126(8):3130\u20133144","journal-title":"J Clin Investig"},{"issue":"14","key":"2850_CR20","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2010-03-275446","volume":"116","author":"Q Zhou","year":"2010","unstructured":"Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M et al (2010) Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 116(14):2484\u20132493","journal-title":"Blood"},{"issue":"7","key":"2850_CR21","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1111\/cas.14069","volume":"110","author":"Yoshihiro Ohue","year":"2019","unstructured":"Ohue Yoshihiro, Nishikawa Hiroyoshi (2019) Regulatory T (Treg) cells in cancer: Can treg cells be a new therapeutic target? Cancer Sci 110(7):2080\u20132089","journal-title":"Cancer Sci"},{"key":"2850_CR22","doi-asserted-by":"crossref","unstructured":"Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB et al (2016) Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to Sorafenib. Gastroenterology 150(7):1646\u201358 e17","DOI":"10.1053\/j.gastro.2016.02.040"},{"issue":"5","key":"2850_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449\u2013459","journal-title":"N Engl J Med"},{"issue":"13","key":"2850_CR24","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2217\/imt-2017-0072","volume":"9","author":"J Liu","year":"2017","unstructured":"Liu J, Zhang X, Zhong JF, Zhang C (2017) CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia. Immunotherapy 9(13):1115\u20131125","journal-title":"Immunotherapy"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02850-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-02850-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02850-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T13:05:49Z","timestamp":1626699949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-02850-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["2850"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-02850-6","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,18]]},"assertion":[{"value":"18 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Medical Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (TJ-IRB20160310).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent in accordance with the Declaration of Helsinki. This study is registered at  as ChiCTR-OPN-16008526.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}